Trials / Completed
CompletedNCT00154362
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 6 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxcarbazepine |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2004-10-01
- Completion
- 2004-10-01
- First posted
- 2005-09-12
- Last updated
- 2011-11-24
Source: ClinicalTrials.gov record NCT00154362. Inclusion in this directory is not an endorsement.